GYNECOLOGIC CANCERS

A phase 3 trial showed that alpelisib plus olaparib did not reduce the risk of progression or death in relapsed/refractory ovarian cancer.

A promising allogeneic CAR T therapy has shown the potential to succeed in ovarian cancer where standard CAR-T treatments have failed.

The results support the potential for treatment de-escalation after hysterectomy for women with early-stage, intermediate-risk cervical cancer.

Katherine McDaniel, MD, a reproductive endocrinologist, discusses the key takeaways for oncologists treating patients of reproductive age.

Katherine McDaniel, MD, discusses the barriers to fertility preservation access for patients diagnosed with cancer.

A recent study characterized the expression of ADC targets across ovarian cancer histotypes. Findings suggest histotype-specific ADC utility, particularly for B7-H4 target.

A recent study highlights disparities in federal cancer funding, revealing that high-mortality cancers like lung and liver are significantly underfunded.

Tislelizumab combined with chemotherapy shows promising antitumor activity in advanced cervical cancer, achieving high response rates and manageable safety profiles.

Emiltatug ledadotin shows promising antitumor activity in various cancers, with manageable safety, highlighting its potential in targeted therapy advancements.

A new FDA application for relacorilant shows promising survival benefits in treating platinum-resistant ovarian cancer, enhancing standard chemotherapy outcomes.

The CDK2 inhibitor INCB123667 showed positive efficacy and safety signals in platinum-resistant/refractory ovarian cancer.

New research reveals PD-L1 expression enhances survival in advanced ovarian cancer, linking it to homologous recombination deficiency and treatment personalization.

New combination therapy of relacorilant and nab-paclitaxel shows promise in extending survival for patients with platinum-resistant ovarian cancer.

Anixa Biosciences advances CAR T-cell therapy for recurrent ovarian cancer, targeting FSHR with promising safety and efficacy in ongoing clinical trials.

New findings reveal mirvetuximab soravtansine significantly improves outcomes in patients with recurrent platinum-sensitive ovarian cancer, regardless of HRD status.

The survival benefit with cadonilimab in cervical cancer in the overall phase 3 COMPASSION-16 study population was sustained across prespecified subgroups.

The FDA granted fast track designation to PHST001 for the treatment of advanced ovarian cancer.

Cervical cancer prevention advances with new immunotherapy findings, addressing disparities and improving outcomes for underserved women globally.

A phase 2 trial shows promising results for pembrolizumab combined with cisplatin and radiation in treating unresectable vulvar cancer.

Undetectable ctDNA at cycle 6 strongly predicts reduced progression/death risk in locally advanced cervical cancer patients treated with durvalumab/CRT or CRT alone.

Adding IMNN-001 to perioperative chemotherapy showed numerical improvements in PFS and OS for newly diagnosed epithelial ovarian cancer, warranting further study.

Relacorilant/nab-paclitaxel significantly improved PFS and OS vs nab-paclitaxel alone in platinum-resistant ovarian cancer.